Portal de Periódicos da CAPES

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

2021; Massachusetts Medical Society; Volume: 384; Issue: 20 Linguagem: Inglês

10.1056/nejmoa2102214

1533-4406

Shabir A. Madhi, Vicky L. Baillie, Clare Cutland, Merryn Voysey, Anthonet Koen, Lee Fairlie, Sherman D. Padayachee, Keertan Dheda, Shaun Barnabas, Qasim Bhorat, Carmen Briner, Gaurav Kwatra, Khatija Ahmed, Parvinder K. Aley, Sutika Bhikha, Jinal N. Bhiman, As’ad E. Bhorat, Jeanine du Plessis, Aliasgar Esmail, Marisa Groenewald, Elizea Horne, Shi-Hsia Hwa, Aylin Jose, Teresa Lambe, Matt Laubscher, Mookho Malahleha, Masebole Masenya, Mduduzi Masilela, Shakeel McKenzie, Kgaogelo Molapo, Andrew Moultrie, Suzette Oelofse, Faeezah Patel, Sureshnee Pillay, Sarah Rhead, Hylton Rodel, Lindie Rossouw, Carol Taoushanis, Houriiyah Tegally, Asha Thombrayil, Samuel van Eck, Constantinos Kurt Wibmer, Nicholas M. Durham, Elizabeth J. Kelly, Tonya Villafana, Sarah C. Gilbert, Andrew J. Pollard, Túlio de Oliveira, Penny L. Moore, Alex Sigal, Alane Izu,

Vaccine Coverage and Hesitancy

Assessment of the safety and efficacy of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is investigation of the efficacy of the vaccines against emerging SARS-CoV-2 variants of concern, including the B.1.351 (501Y.V2) variant first identified in South Africa.